Humoral Immunity in MDs. Partial benefits were observed in LGMD2B patients with intravenous immunoglobulins and Rituximab (anti-CD20) administration; both of these treatments blocked B-lymphocytes which are not a major component of infiltrates in this disease [43], suggesting that further studies are needed to clarify the role of B-lymphocytes in this muscle disease. This evidence concerns the gene DYSF and myelodysplastic syndrome.